Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.
Bedrijven · 27-7-20221 min lezen
Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment of CD19-Expressing Human Cancers
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Capstan Therapeutics (Capstan), located in San Diego, California, the United States of America.
Oorspronkelijke brontaal: Federal Register — Health and Human ServicesOrigineel bericht openen →